Rocuronium Completed Phase 2 Trials for Neuromuscular Blockade Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03519854Efficacy, Safety and Pharmacokinetics of Sugammadex (Org 25969; MK-8616) at 3 Different Time Points After 0.6 mg/kg EsmeronĀ® in Male Participants (P05940; MK-8616-020).
NCT03519867Efficacy and Safety of Org 25969 Administered After ZemuronĀ® (MK-8616-042)